International and EU cooperation

The European Commission and the agencies operating under it support research, development and innovation (RDI) activities in the Member States by offering a wide range of different forms of project funding in accordance with EU policy objectives. Funding may also be granted for the development of public administration and official functions. Key funding programmes include the Horizon Europe, EU4Health and TSI programmes.

Fimea has actively utilised this opportunity and has succeeded in increasing the size of its EU project portfolio. In EU projects, Fimea strives to harmonise its operating processes and coordinate information systems with other Member States’ medicines agencies. Another aim is to develop supervision, reporting and cooperation networks in the pharmaceutical sector.

Fimea’s virtual project office manages the organisation’s EU project portfolio and coordinates EU project activities across areas of responsibility within the organisation. Fimea currently participates in the following ongoing EU projects.

Projects funded by the EU Commission

Safety assessment cooperation and facilitated conduct of clinical trials, project period 05/2022–04/2025.

This project improves the competence and expertise needed for safety assessment cooperation of clinical trials in the Member States. The project will also create a training process and a mentoring programme for new safety assessors.

Read more:

The SAFE CT project on the EU Funding and Tenders Portal
Collecting and reporting data on the volume of sales and use of veterinary antimicrobial medicinal products, project period 12/2022–11/2025.

In this project, Fimea and the Finnish Food Authority promote the automation of the reporting on the consumption of veterinary antimicrobials by designing a database of veterinary medicinal products. In the future, the database will ensure that all actors have access to the same high-quality and up-to-date data on medicinal products. At the same time, a quality management plan is created to ensure the reliability of the sales volume data of veterinary medicines and the information in Fimea’s marketing authorisation and medicinal product register.

Read more:

Joint news article by Finnish Food Authority and Fimea 21.6.2023: Finnish Food Authority and Fimea is developing reporting on the sales and use of veterinary antimicrobials
Quality of medicines and implementation of the pharmaceutical legislation/strategy, project period 01/2023–12/2025.

The project develops an audit programme for GMP between Member States and increases their audit capacity and capabilities by providing additional training for inspectors, for instance.

Read more:

The EU4H-11 project on the EU Funding and Tenders Portal
Coordination and harmonization of the existing systems against shortages of medicines – European network, project period 01/2023–12/2025.

The project harmonises responses to medicine shortages between the Member States’ authorities, thus aiming to reduce these shortages in Europe. Fimea’s tasks in this project focus on preventing medicine shortages and creating operating strategies aimed at minimising their impacts.

Read more:

CHESSMEN's website

CHESSMEN's LinkedIn-page
Reinforced market surveillance of medical devices and in vitromedical devices, project period 11/2023–10/2026.

The project reinforces market surveillance of medical devices between Member States’ authorities by enhancing information sharing and cooperation between inspectors. The project also aims to harmonise audit processes at Union level and to provide more training to inspectors.

Read more:

JAMS 2.0 project's website

JAMS 2.0 project's LinkedIn-page
Improved risk assessment for strategic water management to reduce micro-pollutant emissions in the Baltic Sea Region, project period 11/2023–10/2026.

The project focusses on the emissions and occurrence of medicinal substances in landlocked regions that have received less attention. Previous studies have often been limited to the largest bodies in the largest coastal cities. The aim of the project is to develop a method for assessing the risk of medicinal product load on water bodies caused by wastewater treatment plants.

Read more:

APRIORA project's website
Supporting the increased capacity building of the EU medicines regulatory network, project period 01/2024–11/2026.

The project enhances cooperation and networking between authorities in the pharmaceutical sector. It will also increase capacities needed to respond to future scientific development challenges through expert training, an exchange programme and by sharing best practices between Member States.

Read more:

The IncreaseNET project on the EU Funding and Tenders Portal

#IncreaseNET
Joint Action Antimicrobial Resistance and Healthcare-Associated Infections, project period 01/2024–12/2027.

The project promotes the work against antimicrobial resistance (AMR). Member States develop and update national AMR action plans and increase citizens’ AMR awareness through information campaigns. The project also promotes antimicrobial control measures, reinforces infection prevention and control, and aims to improve the availability of critical medicines.

Read more:

EU-JAMRAI 2 project's website

EU-JAMRAI 2 project's LinkedIn-page

EU-JAMRAI 2 project's X-page

Funding

Co-funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Health and Digital Executive Agency (HaDEA). Neither the European Union nor the granting authority can be held responsible for them.

SAFE CT (no. 101082328), EU4H-11 (no. 101082515), CHESSMEN (no. 101082419), JAMS 2.0 (no. 101127889), IncreaseNET (no. 101124540), APRIORA and EU-JAMRAI 2 (no. 10112787) are projects co-financed by the European Union.

The ASU-FI project (no. 101103224) has received funding from the European Union's Single Market Program (SMP).

Kieliversion valinta

Kieliversion valinta

International and EU cooperation